Adalimumab

HUMIRA

復邁皮下注射劑

40mg/0.4ml/syringes

05.BIOLOGIC AND IMMUNOLOGIC AGENT; ;

05.05. IMMUNOLOGIC AGENTS;;

Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors

1.類風濕性關節炎 2.乾癬性關節炎 3.僵直性脊椎炎
4.克隆氏症 5.乾癬 6.幼年型自發性多關節炎 7.潰瘍性結腸炎

B 動物試驗中無法證實對胎兒有害，但沒有以人做較嚴謹的研究。或動物試驗報告對胎兒有害，但對懷孕婦女有對照組的研究中無法證明對胎兒有害。

Unsafe

Rheumatoid arthritis, psoriatic arthritism,ankylosing spondylitis:
SC 40mg every other week
Crohn’s disease
Initial SC 160mg (given as 4 injections on day 1 or given as 2 injections daily over 2 consecutive days), then 80 mg 2 weeks later (day 15); maintenance 40 mg every other week beginning day 29
Plaque psoriasis
Initial SC 80mg, maintenance 40 mg every other week beginning 1 week after initial dose
Ulcerative colitis
Adult:Initial SC 160mg (given as 4 injections on day 1 or given as 2 injections daily over 2 consecutive days), then 80 mg 2 weeks later (day 15); maintenance 40 mg every other week beginning day 29
20 to <40 kg child:Initial: 80 mg on day 1, then 40 mg administered weekly for 2 weeks
Maintenance (beginning day 29): 40 mg every other week
≥40 kg child: Initial: 160 mg on day 1 (administered as full dose on day 1 or dose split and administered over 2 consecutive days), then 80 mg administered weekly for 2 weeks
Maintenance (beginning day 29): 80 mg every other week

hypertension,injection site reaction, rash, antibody development,antinuclear antibody positive,headache

建立者

100224

建立時間

2008-02-27 11:23:02

維護者

103617

維護時間

2021-12-09 11:03:09